X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PANACEA BIOTECH VENUS REMEDIES/
PANACEA BIOTECH
 
P/E (TTM) x -836.6 145.3 - View Chart
P/BV x 0.2 3.2 7.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PANACEA BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
PANACEA BIOTECH
Mar-14
VENUS REMEDIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs218149 146.6%   
Low Rs8282 99.8%   
Sales per share (Unadj.) Rs365.684.1 434.5%  
Earnings per share (Unadj.) Rs1.5-18.3 -8.1%  
Cash flow per share (Unadj.) Rs37.9-6.7 -566.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.583.7 457.0%  
Shares outstanding (eoy) m11.4461.25 18.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.4 29.9%   
Avg P/E ratio x101.0-6.3 -1,600.5%  
P/CF ratio (eoy) x4.0-17.2 -23.0%  
Price / Book Value ratio x0.41.4 28.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7177,074 24.3%   
No. of employees `0001.02.8 37.1%   
Total wages/salary Rs m3241,449 22.4%   
Avg. sales/employee Rs Th4,100.71,874.1 218.8%   
Avg. wages/employee Rs Th318.0527.0 60.4%   
Avg. net profit/employee Rs Th16.7-407.7 -4.1%   
INCOME DATA
Net Sales Rs m4,1835,154 81.2%  
Other income Rs m20100 20.1%   
Total revenues Rs m4,2035,254 80.0%   
Gross profit Rs m812-766 -105.9%  
Depreciation Rs m417711 58.6%   
Interest Rs m3801,503 25.3%   
Profit before tax Rs m35-2,881 -1.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1817 107.7%   
Profit after tax Rs m17-1,121 -1.5%  
Gross profit margin %19.4-14.9 -130.5%  
Effective tax rate %51.6-0.6 -8,841.6%   
Net profit margin %0.4-21.8 -1.9%  
BALANCE SHEET DATA
Current assets Rs m2,7713,810 72.7%   
Current liabilities Rs m1,9318,365 23.1%   
Net working cap to sales %20.1-88.4 -22.7%  
Current ratio x1.40.5 315.0%  
Inventory Days Days125156 80.3%  
Debtors Days Days5467 79.9%  
Net fixed assets Rs m5,32814,480 36.8%   
Share capital Rs m11461 186.6%   
"Free" reserves Rs m4,177903 462.5%   
Net worth Rs m4,3765,127 85.4%   
Long term debt Rs m1,9115,832 32.8%   
Total assets Rs m8,42819,433 43.4%  
Interest coverage x1.1-0.9 -119.2%   
Debt to equity ratio x0.41.1 38.4%  
Sales to assets ratio x0.50.3 187.1%   
Return on assets %4.72.0 239.7%  
Return on equity %0.4-21.9 -1.8%  
Return on capital %6.63.6 181.5%  
Exports to sales %024.5 0.0%   
Imports to sales %20.510.2 201.5%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs m858525 163.6%   
Fx inflow Rs m01,539 0.0%   
Fx outflow Rs m858942 91.1%   
Net fx Rs m-858597 -143.7%   
CASH FLOW
From Operations Rs m469599 78.2%  
From Investments Rs m29-438 -6.7%  
From Financial Activity Rs m-464-303 153.2%  
Net Cashflow Rs m35-141 -24.4%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 30.0%  
FIIs % 0.6 1.3 44.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.6 281.4%  
Shareholders   20,121 10,259 196.1%  
Pledged promoter(s) holding % 36.4 35.1 103.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  PFIZER  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS